Pressure BioSciences Inc. (OTCQB: PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences industry, today announced a major collaboration with the College of Food, Agricultural, and Environmental Sciences of The Ohio State University ("Ohio State"). The primary goal of the program is to develop and make available for commercialization a continuous-flow manufacturing technology that will prepare liquid foods and beverages with preservation of superior sensory and nutritional qualities, while delivering long, room temperature shelf stability without requiring refrigeration or chemical additives throughout the chain of distribution and retail sale.

Pressure BioSciences Inc. (OTCQB: PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $3.80, up 11.76%, on 454 volume with 4 trades. The average volume for the last 60 days is 1,276 and the stock's 52-week low/high is $0.70/$6.31.

Recent News

• Pressure BioSciences Developing Potential Breakthrough Processing Method for High Quality, Shelf Stable Milk and Other Dairy Products
• NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Collaborates with Ohio State University to Study Ultra-Shear Technology
• Everett Jolly, Host of “Stock Day” Welcomes Richard T. Schumacher of Pressure BioSciences Back on the Show to Discuss Significant Debt to Equity Conversions and other Recent Accomplishments

EVIO, Inc. (OTCQB: EVIO)

The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO).

EVIO Inc. (OTCQB: EVIO), the leading North American provider of cannabis testing and scientific research for the regulated cannabis industry, is pleased to announce that its Licensee, PhytaTech CO, has been awarded Certification for Pesticide Analysis in the State of Colorado.

EVIO, Inc. (OTCQB: EVIO), via the EVIO Labs division, is the nation’s leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation’s cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

• Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
• Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
• Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
• Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
• Detection of harmful residual solvents left behind in the cannabis extract production process.
• Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
• Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation’s leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today’s fastest growing industry.

EVIO, Inc. (EVIO), closed the day's trading session at $1.00, up 3.09%, on 65,465 volume with 73 trades. The average volume for the last 60 days is 99,121 and the stock's 52-week low/high is $0.47/$2.70.

Recent News

• EVIO Labs Colorado Licensee, PhytaTech CO, Receives Certification for Pesticide Contamination Testing
• EVIO Inc. Joins Prestigious Line-Up of Cannabis Business Exhibitors at NCIA's 5th Annual Cannabis Business Summit & Expo
• Cannabis Testing Leader EVIO Inc. (EVIO) Marks Notable Milestones in California, Oregon and Canada

ChineseInvestors.com (OTCQB: CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

Referring to blockchain, the technology that underlies bitcoin and other alt-currencies, Stephen Horan, managing director for general education and curriculum at the CFA Institute, commented, “This is not a passing fad. We saw the field advancing more quickly than other fields and we also saw it as more durable”, according to a Bloomberg report (http://ccw.fm/lES4L). So did ChineseInvestors.com, Inc. (OTCQB: CIIX), which in April 2018 announced plans to launch its Bitcoin Trading Academy. Now the company, which hosts a leading financial information portal for Chinese-speaking investors in mainland China and the Diasporas, has officially launched the program, which offers instruction in cryptocurrency trading (http://ccw.fm/PzG3w).

Founded in 1999, ChineseInvestors.com (OTCQB: CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.39, up 2.77%, on 30,604 volume with 24 trades. The average volume for the last 60 days is 58,609 and the stock's 52-week low/high is $0.37/$1.58.

Recent News

• ChineseInvestors.com, Inc. (CIIX) Leads and CFA Follows in Cryptocurrency Education
• ChineseInvestors.com, Inc. Announces the Official Launch of its New Cryptocurrency Trading Courses Offered Through Bitcoin Trading Academy
• ChineseInvestors.com, Inc. Moves Toward Operating its Own Bitcoin ATM Network in California, With Plans to Expand to Serve Other Chinese Communities Throughout the United States

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (TSX: TGOD).

The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (US:TGODF) (the “Company” or “TGOD”)  is pleased to announce its intention to complete a spinoff transaction by way of plan of arrangement (the “Arrangement”), pursuant to which the Company will distribute a dividend consisting of a warrant (a “Warrant”) in a new corporation (“TGOD Acquisitions”) to shareholders. The new corporation will be engaged in the acquisition and development of worldwide opportunities. To learn more about this dividend and the details behind it contact the investor relations team at: invest@tgod.ca or (416) 900-7621. Also today, the company was highlighted in an article on companies in the sector which are prepared for the forthcoming end of cannabis prohibition.

The Green Organic Dutchman (TSX: TGOD) (OTCQX: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (TSX: TGOD), closed the day's trading session at $5.83, up 2.46%, on 75,420 volume. The stock's 52-week low/high is $3.50/$8.28.

Recent News

• The Green Organic Dutchman to Provide Dividend of TGOD Acquisition Corporation Rewarding Shareholders
• These Marijuana Stocks are Prepared for the End of Cannabis Prohibition
• The Green Organic Dutchman and Epican Open Flagship Retail Dispensary in Jamaica

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF)

The QualityStocks Daily Newsletter would like to spotlight FinCanna Capital Corp. (FNNZF).

FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF) a royalty company for the U.S. licensed medical cannabis industry, is pleased to announce the appointment of Mr. John Campbell to its Advisory Board. Mr. Campbell has over 35 years of experience in the investment industry, and currently serves as Chairman and CFO of TriView Capital, one of Canada’s largest Exempt Market Dealers.

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) is a royalty company aiming to be the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry. Primarily focused on the burgeoning California cannabis market, FinCanna leverages extensive investment expertise and industry experience to benefit its shareholders and portfolio companies.

Medical Cannabis Market

According to Ameri Research, the global market for licensed medical cannabis is growing at a compound annual growth rate (CAGR) of more than 21%, on track to exceed $63.5 billion by 2024. Within this market, FinCanna has identified considerable opportunity in California, the fifth largest economy in the world and the largest medical cannabis market in North America. Arcview Group forecasts California’s legal cannabis industry will grow at 21.1% CAGR to $6.5 billion in 2020, generating more than $1 billion in tax revenue.

Royalty Model & Portfolio

FinCanna’s “whole capital” solution for businesses in the licensed medical cannabis sector includes the provision of capital investment for a percentage of their future revenues. The FinCanna Capital Solution utilizes a royalty arrangement to deliver capital, in order to facilitate the growth or other specific objectives of its investees, and ensure the business opportunity is optimized. This model provides an alternative or complement to debt and equity financing, allowing investees to maintain financial flexibility and control of their business rather than entering into arrangements that may include restrictive debt structures or giving up an ownership stake.

FinCanna’s portfolio includes Cultivation Technologies, Inc. (“CTI”), a team of experts from Fortune 150 agriculture, medical cannabis, law, engineering and technology companies. FinCanna is providing funding to CTI for its planned, fully entitled, large-scale indoor medical cannabis facility to be developed in Coachella, California.

CTI has established an interim medical cannabis extraction facility (the “Interim Facility”) that will produce licensed medical cannabis products until the Coachella Project is complete. CTI is currently expanding its product line, Coachella Premium, to include vaporizer cartridges. Initial market feedback gathered during the product development phase indicates that Coachella Premium’s vaporizer cartridges offer a unique proposition within the vaporizer market, one of the fastest growing verticals in the cannabis market.

The Interim Facility can process up to 6,000 pounds of biomass per month, the equivalent of approximately 3.7 million grams of raw oil per year, with room for expansion. It is expected that the completed Coachella Project will be able to process 30,000 to 50,000 pounds of biomass per month, or the equivalent of 18 million grams to 30 million grams of raw oil per year.

Additionally FinCanna has entered into a royalty agreement with Green Compliance, a provider of point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators. Green Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations.

FinCanna has also signed binding term sheet with Oakland, California-based Gram Co Holdings, subject to due diligence by FinCanna. Gram Co is a cannabinoid research and refinement facility focused providing B2B and B2C products and services to licensed medical dispensaries, infused product manufacturers, and numerous others in the cannabis supply chain. The company is also retrofitting a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating in 2018.

The foregoing contains forward-looking statements regarding Cultivation Technologies Inc. (“CTI”) which are subject to risks, uncertainties and contingencies which include, but are not limited to the statements relating the future construction and completion of the CTI medical cannabis facility in Coachella, California, and the projected biomass processing and raw oil production at the facility. Such forward looking statements are based on assumptions regarding the construction, completion and operations of CTI’s proposed facility, including that CTI will obtain the financing required to build and equip its proposed facility, that CTI will obtain the additional financing required operate the facility, that construction facility is completed on time and budget, that CTI obtains state licenses to operate on a permanent basis, and that the equipment used in the cultivation of medical cannabis performs at scale in a similar way it performs at CTI’s pilot tests.

FinCanna Capital Corp. (FNNZF), closed the day's trading session at $0.2214, up 8.11%, on 19,688 volume with 20 trades. The average volume for the last 60 days is 45,348 and the stock's 52-week low/high is $0.10/$0.8736.

Recent News

• FinCanna Capital Welcomes John Campbell to its Advisory Board
• FinCanna Investment, CTI Executes Exclusive Manufacturing and Distribution Agreement with Phoenix Tears for its THC Based Products in California
• FinCanna Executes & Increases Royalty Payments Under Agreement with Refined Resin Technologies Inc. a California Based Cannabis and Extraction Company

American Helium (TSX.V: AHE) (OTC: AHELF)

The QualityStocks Daily Newsletter would like to spotlight American Helium (AHELF).

American Helium Inc. (TSX.V: AHE) (OTC: AHELF) (XFRA: 43UB), a resource exploration company focused on the global growth of technology-driven demand for helium. The Company was formed in 2017 around the Bruin Point acreage in Carbon County, Utah.

American Helium (TSX.V: AHE) (OTC: AHELF) is a resource exploration company focused on the global growth of technology-driven demand for helium and the development of high grade helium resources in North America. Through such activities, it strives to contribute to the global helium inventory and become an industry leading producer.

The Canadian helium exploration and development company is led by an experienced management and technical team. The Company is currently focused on three properties in prolific areas for Helium exploration.

Recently, the company executed an agreement with Holbrook Basin Energy LLC of Golden, CO to undertake an exploration drill program in Arizona. The Arizona project location is in the “Four Corners” area where the States of Utah, Colorado, New Mexico and Arizona meet, and in the helium productive Holbrook Basin, a well-established helium production district where concentrations of the gas are as high as 10%. The area has good potential for additional discovery and production. The abundant nature of the region has led to anecdotal statements over the years that “Arizona is the Saudi Arabia of helium.”

The Company holds 100 percent working interest and 87.5 percent net revenue interest in 12 federal leases at its Bruin Point property spanning across 17,000 acres in the Greater Uintah Basin, Carbon County, Utah (the Carbon County project). American Helium is undertaking preparations for the drilling of an exploration well, and as part of that process a Notice of Staking (NOS) has been filed with the offices of the Bureau of Land Management (BLM).

Evaluation is currently ongoing to determine potential additional acquisitions in regions that are known for their helium production. The Company is planning exploration wells with the prospect of capturing new resources and improving the Company’s market position during the year.

The Company has also executed a project agreement with Yankee Resources LLC of Golden, CO and has appointed LoneTree Energy & Associates LLC to acquire certain acreage in SE Colorado. The project consists of two parts. The first objective is to re-drill two wells that have proven helium resources. Both were plugged and abandoned in the mid-nineties, offering the potential for near term production. The second part of the project will offer an exploration focus through the acquisition of land and a subsequent 3D seismic survey aimed at further defining areas of likely helium accumulations.

The company set up a Denver satellite office aimed at overseeing the regional operations in Utah better and at facilitating expansion in SE Colorado. Company President and CEO Frank Jacobs, a petroleum engineer with 35+ years of operational experience, will oversee U.S.-based operations.

Global helium demand is driven by a number of different industries. Primarily, the military, healthcare, nuclear, aviation and electronics. A colorless, odorless and non-toxic gas, helium is lighter than air and it has the lowest boiling point of all elements. This property makes it essential for a wide variety of tech based applications.

The U.S. ranks as the largest producer and consumer of helium. North America accounts for approximately a third of the world’s helium consumption (2.6 billion cubic feet of helium per year). The world’s annual consumption of helium is set at eight billion cubic feet per year. As far as production goes, the U.S. is responsible for 55 percent of the global helium supply. Qatar, Algeria and Russia come next.

The fact that production efforts have been centralized and focused in just a few countries has long been a source of industry concern. “The concentration of production among a handful of countries will continue to be the leading driver of uncertainty of helium supply and price volatility. We are working to identify, explore and place into production helium assets. With the right assets and the necessary funding we are confident we can achieve this objective ,” Frank Jacobs said.

The price of helium has doubled since 2010 because this unique gas cannot be substituted in its applications. In addition, a Qatar production blockage has had a massive negative impact on the helium supply. In the summer of 2017, Qatar’s RasGas closed down both of its plants, responsible for approximately 32 percent of the global helium demand. This shift has contributed to highly favorable supply and demand fundamentals for the remaining market players.

Experts predict that the demand for the gas will continue to grow in the years to come. The global helium market set to exceed $1.5 billion by 2020, advancing at a compound annual growth rate of 9 percent, according to Technavio analysts. Over 20 percent of the global helium demand is for healthcare applications. MRI machines are being installed in hospitals more frequently than ever before, potentially increasing the demand for helium in the medical industry. Innovative aerospace projects and technical applications are also expected to elevate the helium market forecasts in the years to come. Large corporations such as Google and Netflix have both been buying up significant amounts of helium, as the gas can increase the storage capacity of hard drives while also bringing down power consumption.

Additional information about the American Helium research and exploration activities will become available in the months to come. The company is positioning itself to capture the numerous opportunities stemming from increasing helium prices and the growing global demand.

American Helium (AHELF), closed the day's trading session at $0.147, off by 13.73%, on 100 volume with 1 trade. The average volume for the last 60 days is 21,698 and the stock's 52-week low/high is $0.1497/$0.77.

Recent News

• American Helium Provides Shareholder Update
• NetworkNewsBreaks – Why American Helium (TSX.V: AHE) (OTC: AHELF) is “One to Watch”
• American Helium Inc. (TSX.V: AHE) (OTC: AHELF) is “One to Watch”

Virtual Crypto Technologies Inc. (OTCQB: VRCP)

The QualityStocks Daily Newsletter would like to spotlight Virtual Crypto Technologies Inc. (VRCP).

Virtual Crypto Technologies Inc. (OTCQB: VRCP), through wholly owned Israeli subsidiary Virtual Crypto Technologies Ltd., dedicated to the mission of making cryptocurrencies accessible to the public, has developed a platform that is connected to crypto exchanges, allowing cryptocurrencies to be bought and sold with fiat currencies. By linking to numerous exchanges, Virtual Crypto’s NetoBit ATM platform increases bitcoin liquidity. With increased access to buyers and sellers, getting in and out of bitcoin has never been easier.

Virtual Crypto Technologies Inc. (OTCQB: VRCP) is a developer of software and hardware for the purchase and sale of cryptocurrencies through ATMs, tablets, PCs and mobile devices. The company’s proprietary algorithmic technology trading platform, called NetoBit Trader, can instantaneously confirm the purchase or sale of Bitcoin, a process that typically can take between 10 minutes to 24 hours. All trades and exchanges are insured up to $3,000 per trade. The global cryptocurrency ATM market is predicted to surpass $285 million by 2025, yet, at present, only 30 percent of these machines allow two-way trades.

With NetoBit Trader, cryptocurrency holders enjoy immediate confirmation of Bitcoin and its crypto equivalents at the best crypto exchange rate at the point of transaction – providing a major breakthrough in the quest to bring cryptocurrencies to the mass market. Virtual Crypto’s cryptocurrency ATM, embedded with currency exchange transaction validation (CETV) in its hardware and software, accepts and dispenses cash and cryptocurrency in seconds.

Virtual Crypto’s NetoBit Trader and mobile retail point-of-sale platform incorporates advanced technologies tailored to the needs of primary market players, users, investors, and business owners. Virtual Crypto’s platform bridges the three main functions of the cryptocurrency sector – exchanges, wallets and payments – to the world of fiat exchanges, granting access to immediate cash exchanges between consumers and businesses worldwide.

NetoBit Trader’s over-the-counter, two-way transaction solution is available through one app, providing online cryptocurrency transactions at ecommerce and gaming portals. The app provides real-time cryptocurrency validation and exchange, easy buying and selling of Bitcoin with cash, enables traders to buy and trade crypto, and gamers to transfer cryptocurrency into cash after play. Crypto users can withdraw funds from their crypto accounts through a NetoBit cryptocurrency ATM or software-enabled tablet, and consumers can purchase retail with crypto from businesses that offer and use the NetoBit software.

The company’s newly redesigned corporate website, www.virtual-crypto.com, delivers a simple, clean design with enhanced functionality, features and navigation. Virtual Crypto’s new corporate website includes:

• Downloadable NetoBit Trader app link and contact forms for more information
• MarketWatch provides real-time tracking of the Bitcoin market, with other currencies to follow
• Improved security utilizing https certificates to protect personal information and site integrity
• Media room with downloadable product brochures, corporate presentations and other relevant content
• Investor’s page provides transparency to investors with direct access to Virtual Crypto’s progress through press releases, SEC filings, senior management team bios, and stock performance charts
• Social Media integration with buttons for LinkedIn, Twitter and Facebook jump to Virtual Crypto’s social media profiles, providing real-time updates from the online community

“Our primary objective is to make cryptocurrencies accessible to everyone, and that was the motivation for our redesign,” said Alon Dayan, Chief Executive Officer of Virtual Crypto. “The updated content provides real value for our customers, shareholders and employees, showcasing our products and services, in an intuitive, easy to navigate way.”

Virtual Crypto’s strategic vision of “Cryptocurrency Made Easy” allows crypto traders and users to overcome the complex hurdles currently hampering the cryptocurrency sphere.

Virtual Crypto Technologies Inc. (VRCP), closed the day's trading session at $0.12, even for the day, on 13,860 volume with 10 trades. The average volume for the last 60 days is 37,116 and the stock's 52-week low/high is $0.0125/$0.38.

Recent News

• Virtual Crypto Technologies Inc. (VRCP) Facilitates Cryptocurrency Convenience and Liquidity with ATM Gateway
• CryptoNewsAudio Announces Audio Press Release (APR) on Virtual Crypto Technologies Inc. Leading Shift to Better Business with Blockchain
• CryptoCurrencyWire Announces Blockchain Revolution Transforming Global Finance

GTX Corp (OTC: GTXOD)

The QualityStocks Daily Newsletter would like to spotlight GTX Corp (GTXOD).

GPS technology-focused holding company GTX Corp (OTC: GTXOD) this morning announced its engagement of Doost, Inc., a boutique sales and business development agency focused on bridging the gap between big box retailers and technology companies. To view the full press release, visit: http://nnw.fm/n72tZ.

GTX Corp (OTC: GTXOD) designs, manufactures and commercializes various products and services in the GPS tracking and monitoring business.  Operating domestically and internationally, via two subsidiaries engaged in the internet of things (IoT) and wearable technology industry. Founded in 2002 and headquartered in Los Angeles, California, the company is a pioneer in Smart GPS, cellular and Bluetooth Low Energy (BLE) tracking technology, offering complete, end-to-end tracking solutions through a proprietary IoT enterprise monitoring platform – the IoT Machine to Machine platform – backed by state-of-the-art hardware, software and connectivity solutions, patents and software algorithms.

Operating under the motto “We Put the ‘Where’ in Wearable Tech,” GTX’s main goal is to keep its customers connected to who and what matters most, with each of its patented tracking technologies providing real-time location coordinates on a map via a personalized portal. The company prides itself on offering not only technologies, but also effective solutions that provide safety, security and peace of mind by helping customers locate their loved ones or lost valuable items.

With a portfolio that includes more than 80 patents filed and issued and with products and services available in 35 countries, GTX’s tracking solutions use the latest in miniaturized, low-power GPS, mobile, RF and BLE technology, that can integrate seamlessly with multiple consumer products, enterprise and military applications. The company became a U.S. Military contractor in 2017 and is already developing asset and human tracking technology for the U.S. Air Force. Its list of customers also includes public health authorities and municipalities, emergency and law enforcement, NGOs, private companies, public and private senior care homes, and consumers.

The company’s flagship product is the award-winning GPS SmartSole®, the world’s first invisible wearable tracking device created specifically for people at risk of wandering, becoming lost or disoriented, including patients with Alzheimer’s, autism, dementia, traumatic brain injury and other cognitive problems. According to the World Alzheimer Report 2013 (http://nnw.fm/mrcV2), there are more than 100 million people worldwide who need constant care and monitoring because of a cognitive disorder, and their number is expected to rise to 277 million by 2050. Due to its hidden location – inside a shoe insert, the device can also be used by people undercover or at risk of kidnapping, such as government agents, military personnel, law enforcement, journalists, corporate executives, etc.

Other tracking devices designed and commercialized by the company for civilian or military use include:

• Take-Along Tracker 3G: A powerful mini-tracking device with GPS, 2G and 3G GSM data and voice capabilities, as well as a motion sensor and sleep mode. The device can be easily attached to a keychain, lanyard, dog collar, pocket, bag or plush toy for a discreet but advanced tracking solution.
• Invisabelt: Designed for children, this slim GPS tracker hidden inside a small waistband belt has a battery life of up to two days and is a great solution for parents who want to monitor their children’s location at all times.
• Track My Workforce: An easy and cost-effective solution that allows businesses to track and monitor their mobile workforce. The app is available for both Android and iOS systems, and allows employers to monitor their workforce from a single company account.
• E.T.S. -Personnel Equipment Tracking System: Currently in use at the Edwards Air Force Base, this tracking system allows real-time monitoring and surveillance of personnel and assets and has a 200+ square mile coverage. Solar powering capabilities and extend battery life allow the tracker to be used in areas without existing power sources.
• GPS Rifle Tracker: The company’s smallest GPS tracker, designed to withstand shocks and water submersion due to its robust, military standard enclosure, can be mounted on any AR15 platform picatinny rail to detect weapon discharge, track weapons and inventory, and send time and location alerts.

Led by a management team with solid experience in wearable technology, IoT, consumer electronics, mobile and technology licensing, as well as finance and the footwear industry, GTX plans to leverage its core technology platform to reach new verticals via licensing agreements and strategic partnerships, and to monetize its intellectual property portfolio. The monetization campaign kicked off in 2017 has already identified 100 companies that could become licensees. Besides military and law enforcement, the company also eyes the biometrics market, home health, medicare and insurance and other security applications for potential uses of its IoT platform and tracking technology.

GTX currently has 15 domestic and international distributors, subscribers in 35 countries and more than 700 online affiliates. With multiple revenue streams, several consecutive years of double-digit revenue growth and a strong pipeline of lucrative commercial products, GTX is uniquely positioned to become a leading provider of tracking solutions on this growing multi-billion-dollar market.

GTX Corp (GTXOD), closed the day's trading session at $0.1493, off by 0.40%, on 58,494 volume with 24 trades. The average volume for the last 60 days is 552,970 and the stock's 52-week low/high is $0.1013/$0.20.

Recent News

• NetworkNewsBreaks – GTX Corp (GTXOD) Announces Engagement of Boutique Sales and Business Development Agency
• GTX Corp (GTXOD) Sees ‘Milestone’ Events in Proposed Uplisting, Reverse Split and $1M Premium-To-Market Financing from New Strategic Partner
• NetworkNewsBreaks – GTX Corp (GTXOD) Secures Million Dollar Institutional Financing Round at 10x Valuation

First Cobalt Corp. (TSX-V: FCC) (OTCQX: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF).

First Cobalt Corp. (TSX-V: FCC; ASX: FCC; OTCQX: FTSSF) (the "Company") is pleased to announce that drilling from underground at the Iron Creek Cobalt Project in Idaho, USA continues to extend mineralization beyond the extents of the historic resource. Results from six drill holes completed at the western extension of the mineralized zones validate previously reported intersections which have, to date, extended the total strike length of the Waite Zone to 520 metres along a dip length of more than 250 metres. Also today, the company was featured in a report on growing concerns over the sourcing of cobalt from places such as makeshift mines in the Democratic Republic of Congo (DRC), a problem which threatens the vital cobalt supply chain.

First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance.

First Cobalt Corp. (FTSSF), closed the day's trading session at $0.30, off by 1.90%, on 243,098 volume with 81 trades. The average volume for the last 60 days is 196,092 and the stock's 52-week low/high is $0.2644/$1.3041.

Recent News

• First Cobalt Drilling at Iron Creek Extends Mineralization of Waite Zone
• Indonesia May Provide Answer For Electronic Industry’s Growing Cobalt Problem
• First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) Reports Encouraging Cobalt Assay Results in Canada, Adds Drill Rigs to Idaho Project

Koios Beverage Corp. (CSE: KBEV) (OTC: SNOVF)

The QualityStocks Daily Newsletter would like to spotlight Koios Beverage Corp. (SNOVF).

CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Koios Beverage Corp (CSE:KBEV) (OTC:SNOVF) and their expansion into Cannabis Functional Beverages.

Koios Beverage Corp. (CSE: KBEV) (OTC: SNOVF) develops and distributes nature-based products that boost brain function, enhance health, and improve productivity. Its core vision is to help a billion people worldwide live more productively through the development of nootropics, which are supplements that improve cognitive abilities.

The company’s flagship product, Koios, is a GMP-certified dietary supplement. Made from natural ingredients and backed by science, Koios is designed to improve focus, memory, mental drive, clarity and energy. The company produces Koios in the following formulations:

• Powder supplements containing nootropics as well as caffeine and lion’s mane and chaga mushrooms;
• Vegan-friendly capsules;
• Canned beverages containing nootropics along with MCT oil to burn fat and increase metabolism.

Not to be mistaken with prescription-only drugs which are at times used for similar effects, nootropics are over-the-counter dietary supplements; some of which, like Koios, contain ingredients that are currently used in the treatment of patients with Alzheimer’s disease. The global field of nootropics is growing rapidly and expected to reach USD $6,059.4 Mn by 2024 with a CAGR of 17.9 percent from 2016 to 2024.

According to media reports, there is believed to be significant and growing use of nootropics among high-achieving students and professionals. The UK’s leading Guardian newspaper found that nootropics are commonly used in Silicon Valley by computer industry professionals who want to “hack” their minds and maximize their productivity without any possible negative effects on the brain.

Koios was born out of the personal struggles of its founder and CEO, Chris Miller, who has ADHD. Miller found that the symptoms of his condition held him back when navigating the competitive modern workplace. Unhappy with the effects of the Adderall he was prescribed, Chris began a search for a natural remedy that would improve his attention and mental capacity.

Speaking of his struggles at this time, Miller says, “Coffee and energy drinks were no longer helping me. Eventually, I was drinking so much caffeine that I was beginning to notice negative and troubling health effects.” He adds, “I believed there had to be a better way. Better technology that the earth was providing that I could implement and not only boost my daily performance but take care of my brain and body long-term.” After years of experiments and with the help of leading scientists, he developed Koios, named after the Greek Titan who represented rational intelligence.

Koios contains the following ingredients, among others:

• Vitamin B12: Crucial for the function of the nervous system and the synthesis of DNA, B12 also helps in the creation of red blood cells.
• Vitamin B6: This vitamin is crucial for brain development among children and brain function in adults. B6 is also important in the production of key hormones: serotonin, which regulates mood, norepinephrine, which helps us handle stress, and dopamine.
• Huperzine A: Developed from the Chinese club moss plant, huperzine A is used on Alzheimer’s patients to boost their memories. It is also used to raise energy levels and alertness and is the subject of medical trials to test its efficacy when combined with other drugs.
• Bacopa: Also known as brahmi, bacopa is an Indian herb used in Ayurvedic medicine to improve concentration and memory. Modern science has recognized its effectiveness, and it is used to treat symptoms caused by Alzheimer’s disease, ADHD and anxiety.
• Ciwujia: Sports scientists have been interested in this herb since they heard of how mountain climbers in Tibet use it to boost their performance at high altitudes. Peer-reviewed research has shown that Ciwujia has clear positive effects on endurance.

A full breakdown of Koios’ active ingredients is available on the company website.

Additionally, safety is paramount for Koios, with all its products developed in a high-grade nutraceutical laboratory which is GMP-certified and in compliance with FDA guidelines. Koios only uses high-quality ingredients sourced from the best possible locations in order to deliver a product that is not only safe but also “one of the world’s greatest nootropic blends.”

The company’s products can be found online and in stores, both across the United States and internationally, via a continuously growing distribution network.

Koios CEO Chris Miller is supported by a team with strong credentials in medical supplement start-ups, corporate finance and sales, which includes CFO/Director Anthony Jackson, Director Scott Walters, Director Konstantine Lichtenwald and Vice President of Sales Gina Burrus.

With people seeking a mental edge and cognitive boost, Koios believes that there is an opening in the market for its nature-based, over-the-counter nootropics, especially when current prescription medicines have worrying side effects..

Koios Beverage Corp. (SNOVF), closed the day's trading session at $0.1497, off by 2.48%, on 12,452 volume with 11 trades. The average volume for the last 60 days is 60,765 and the stock's 52-week low/high is $0.001/$0.5121.

Recent News

• CFN Media: Koios Expands into Cannabis Functional Beverages
• Koios Reaches Distribution Deal with Nation-Wide Sports Retailer
• Koios Launches Direct Shipping to Canada

Earth Science Tech, Inc. (OTC: ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (OTC: ETST), a biotechnology company focused on cannabidiol (CBD), nutraceuticals, pharmaceuticals and medical devices, shared progress on its CBD patent formulas in a recent press release (http://cnw.fm/D0PLq). The company has three new CBD formulas under the provisory patent and three Bionatus products in various stages of development.

Earth Science Tech, Inc. (OTC: ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

• Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
• Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
• KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.7099, off by 8.98%, on 25,775 volume with 18 trades. The average volume for the last 60 days is 12,022 and the stock's 52-week low/high is $0.324/$1.62.

Recent News

• Earth Science Tech, Inc. (ETST) Shares Progress on CBD Formulas
• Earth Science Tech, Inc. (ETST) Selects Hygee Name for MSN-2 Home Medical Testing Kit, Sets Prelaunch Clinical Study in Quebec
• Earth Science Tech, Inc. Shares Progress on its Cannabis (CBD) Patent Formulas

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on PreveCeutical Medical Inc. (OTCQB: PRVCF), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.0295, off by 13.24%, on 1,235,514 volume with 90 trades. The average volume for the last 60 days is 456,178 and the stock's 52-week low/high is $0.002/$0.20.

Recent News

• PreveCeutical Medical, Sol-Gel CBD Nasal Delivery Platform, an Innovation in the Cannabis Sector
• PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) CEO Outlines Next Steps for Promising New Technologies
• PreveCeutical Provides Update on Sol-gel Drug Delivery Program

Marijuana Company of America Inc. (OTC: MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Marijuana Company of America Inc. (OTC:MCOA), a client of CNW that focuses on product research and development of legal hemp-based consumer products containing CBD under the brand name “hempSMART™”, an affiliate marketing program to promote and sell its products, as well as leasing of real property and expansion of business into ancillary areas of the legalized cannabis and hemp industry. To view the full publication, titled “Hemp CBD Products Offer a Natural Alternative to Synthetic-Derived Medicines,” visit: http://cnw.fm/gFA62.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0316, off by 9.71%, on 11,685,102 volume with 347 trades. The average volume for the last 60 days is 7,578,116 and the stock's 52-week low/high is $0.022/$0.0728.

Recent News

• CannabisNewsWire Announces Companies Exploring Potential of Natural CBD Options to Synthetic Meds
• Hemp CBD Products Offer a Natural Alternative to Synthetic-Derived Medicines
• Change in Legal Status Likely to Drive Unprecedented Growth in Hemp Industry